FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1011-1020 March 9, 2006 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Hoofnagle, J. H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article

ABSTRACT

Background Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B.

Methods In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue to receive 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end point was histologic improvement (a decrease by at least two points in the Knodell necroinflammatory score, without worsening of fibrosis).

Results Histologic improvement after 48 weeks of treatment occurred in 208 of 296 patients in the entecavir group who had adequate baseline liver-biopsy specimens that could be evaluated (70 percent), as compared with 174 of 287 such patients in the lamivudine group (61 percent, P=0.01). More patients in the entecavir group than in the lamivudine group had undetectable serum hepatitis B virus (HBV) DNA levels according to a polymerase-chain-reaction assay (90 percent vs. 72 percent, P<0.001) and normalization of alanine aminotransferase levels (78 percent vs. 71 percent, P=0.045). The mean reduction in serum HBV DNA levels from baseline to week 48 was greater with entecavir than with lamivudine (5.0 vs. 4.5 log [on a base-10 scale] copies per milliliter, P<0.001). There was no evidence of resistance to entecavir. Safety and adverse-event profiles were similar in the two groups.

Conclusions Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine. The safety profile of the two agents was similar, and there was no evidence of viral resistance to entecavir. (ClinicalTrials.gov number, NCT00035789 [ClinicalTrials.gov] .)

Source Information

From the Queen Mary Hospital, Hong Kong, China (C.-L.L.); Hadassah-Hebrew University Hospital, Jerusalem, Israel (D.S.); University of Michigan, Ann Arbor (A.S.L.); National Cheng Kung University Medical College, Tainan, Taiwan (T.-T.C.); Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (H.C.); Armed Forces Institute of Pathology, Washington, D.C. (Z.G.); University of Connecticut, Farmington (D.D.); and Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Conn. (R.W., R.C.Z., A.C., R.C., L.F.).

Address reprint requests to Dr. Lai at the University Department of Medicine, Queen Mary Hospital, Hong Kong, China, or at hrmelcl{at}hkucc.hku.hk.

Full Text of this Article

This article has been cited by other articles:

• Lacombe, K., Bottero, J., Lemoine, M., Boyd, A., Girard, P. M. (2009). HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother 0: dkp414v1-dkp414 [Abstract] [Full Text]  
• Tong, C. Y. W., Mullen, J. E., Wong, T. (2009). Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations. J Antimicrob Chemother 64: 875-877 [Full Text]  
• Scarsi, K. K., Darin, K. M. (2009). Chronic Hepatitis B Infection: Principles of Therapy. Journal of Pharmacy Practice 22: 359-387 [Abstract]  
• Yuen, M.-F., Lee, S.-H., Kang, H.-M., Kim, C. R., Kim, J., Ngai, V., Lai, C.-L. (2009). Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. Antimicrob. Agents Chemother. 53: 1779-1785 [Abstract] [Full Text]  
• Kaiser, T., Moessner, J., Patel, K., McHutchison, J. G, Tillmann, H. L (2009). Life threatening liver disease during treatment with monoclonal antibodies. BMJ 338: b508-b508 [Full Text]  
• Shamliyan, T. A., MacDonald, R., Shaukat, A., Taylor, B. C., Yuan, J.-M., Johnson, J. R., Tacklind, J., Rutks, I., Kane, R. L., Wilt, T. J. (2009). Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference. ANN INTERN MED 150: 111-124 [Abstract] [Full Text]  
• Tchesnokov, E. P., Obikhod, A., Schinazi, R. F., Gotte, M. (2008). Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase. J. Biol. Chem. 283: 34218-34228 [Abstract] [Full Text]  
• Dienstag, J. L. (2008). Hepatitis B Virus Infection. NEJM 359: 1486-1500 [Full Text]  
• Lau, D. T.-Y., Bleibel, W. (2008). Review: Current status of antiviral therapy for hepatitis B. Therapeutic Advances in Gastroenterology 1: 61-75 [Abstract]  
• Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]  
• Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., Naoumov, N. V., Di Bisceglie, A. M., Zeuzem, S., Moon, Y. M., Goodman, Z., Chao, G., Constance, B. F., Brown, N. A., the Globe Study Group, (2007). Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. NEJM 357: 2576-2588 [Abstract] [Full Text]  
• Chan, H. L.Y., Heathcote, E. J., Marcellin, P., Lai, C.-L., Cho, M., Moon, Y. M., Chao, Y.-C., Myers, R. P., Minuk, G. Y., Jeffers, L., Sievert, W., Bzowej, N., Harb, G., Kaiser, R., Qiao, X.-J., Brown, N. A., and the 018 Study Group, (2007). Treatment of Hepatitis B e Antigen Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. ANN INTERN MED 147: 745-754 [Abstract] [Full Text]  
• Wong, D. K.-H., Tanaka, Y., Lai, C.-L., Mizokami, M., Fung, J., Yuen, M.-F. (2007). Hepatitis B Virus Core-Related Antigens as Markers for Monitoring Chronic Hepatitis B Infection. J. Clin. Microbiol. 45: 3942-3947 [Abstract] [Full Text]  
• Vilarinho, S., Ogasawara, K., Nishimura, S., Lanier, L. L., Baron, J. L. (2007). Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc. Natl. Acad. Sci. USA 104: 18187-18192 [Abstract] [Full Text]  
• Valsamakis, A. (2007). Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B. Clin. Microbiol. Rev. 20: 426-439 [Abstract] [Full Text]  
• Lim, C. Y., Kowdley, K. V. (2007). Optimal duration of therapy in HBV-related cirrhosis. J Antimicrob Chemother 60: 2-6 [Abstract] [Full Text]  
• Langley, D. R., Walsh, A. W., Baldick, C. J., Eggers, B. J., Rose, R. E., Levine, S. M., Kapur, A. J., Colonno, R. J., Tenney, D. J. (2007). Inhibition of Hepatitis B Virus Polymerase by Entecavir. J. Virol. 81: 3992-4001 [Abstract] [Full Text]  
• Tenney, D. J., Rose, R. E., Baldick, C. J., Levine, S. M., Pokornowski, K. A., Walsh, A. W., Fang, J., Yu, C.-F., Zhang, S., Mazzucco, C. E., Eggers, B., Hsu, M., Plym, M. J., Poundstone, P., Yang, J., Colonno, R. J. (2007). Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present. Antimicrob. Agents Chemother. 51: 902-911 [Abstract] [Full Text]  
• Shi, M., Wang, R. S., Zhang, H., Zhu, Y. F., Han, B., Zhang, Y., Jin, L. J., Yang, Z.-J., Xu, Y. P. (2006). Sequential treatment with lamivudine and interferon-{alpha} monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother 58: 1031-1035 [Abstract] [Full Text]  
• Yan, J.-H., Bifano, M., Olsen, S., Smith, R. A., Zhang, D., Grasela, D. M., LaCreta, F. (2006). Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.. J Clin Pharmacol 46: 1250-1258 [Abstract] [Full Text]  
• Chang, T.-T., Lai, C.-L., Schildgen, O., Sirma, H., Gerlich, W. (2006). Hepatitis B virus with primary resistance to adefovir.. NEJM 355: 322-323 [Full Text]  
• (2006). Entecavir vs. Lamivudine for Chronic HBV Infection. JWatch Gastroenterology 2006: 1-1 [Full Text]  
• Osborn, M. K., Lok, A. S. F. (2006). Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 57: 1030-1034 [Abstract] [Full Text]  
• (2006). Entecavir Highly Efficacious for Chronic Hepatitis B. JWatch Infect. Diseases 2006: 3-3 [Full Text]  
• (2006). Entecavir for Chronic Hepatitis B. JWatch General 2006: 1-1 [Full Text]  
• Hoofnagle, J. H. (2006). Hepatitis B -- Preventable and Now Treatable. NEJM 354: 1074-1076 [Full Text]